Antagonistic bombesin-based peptides have shown several other advantages compared to agonists such as more favourable biodistribution and targeting properties, and more binding sites available for targeting than agonists, which may make them preferable over agonists for in vivo tumour targeting [23,24,25,26,27]. The gene discussed is GRP; the disease is neoplasm.